Skip to content

Xtant Medical Holdings XTNT Finite Lived Intangible Assets Amortization Expense Rolling Year Five

Other financials

Income statement

See full
Revenue$20.9M-36.5%
Gross profit$12.0M-40.9%
Operating income-$2.9M-375%
Net income-$3.1M-5,426%
EPS (diluted)-$0.02

Balance sheet

See full
Cash & equivalents$12.2M+124%
Total debt$15.0M-34.9%
Total equity$48.6M+10.8%
Total assets$78.0M-18.6%

Cash flow

See full
Operating cash flow-$2.1M-265%
CapEx$194.0K-83.7%
Free cash flow-$2.3M-2,753%

Valuation

See full
Market cap$59.05M-32.5%
Enterprise value$61.89M-41.5%
P/E32.3×
P/S0.5×-0.2×

Profitability

See full
Gross margin62.3%+4.2pp
Operating margin4.8%+2.8pp
Net margin1.5%+0.8pp
FCF margin6.4%+4.1pp

Returns & leverage

See full
Return on equity3.9%+2.1pp
Debt / equity0.3×-0.2×
Current ratio3.3×+1.0×

Where this comes from

Reported directly by Xtant Medical Holdings in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive.

The official record: Xtant Medical Holdings’s 10-K, filed March 31, 2026, on SEC EDGAR. View the filing →

Ask your AI about Xtant Medical Holdings's finite lived intangible assets amortization expense rolling year five.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Xtant Medical Holdings's finite lived intangible assets amortization expense rolling year five?
Xtant Medical Holdings (XTNT) reported finite lived intangible assets amortization expense rolling year five of $33K in Q4 2025.
What is the long-term trend for Xtant Medical Holdings's finite lived intangible assets amortization expense rolling year five?
Over 2 years (2023 to 2025), Xtant Medical Holdings's finite lived intangible assets amortization expense rolling year five has grown at a -86.0% compound annual growth rate (CAGR), from $1.68M to $33K.